A Phase 4 interventional study of varenicline and placebo in Smoking Cessation, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-08-31.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.
Among the 110 studies testing varenicline in Smoking Cessation, this one is the 68th largest by enrollment, is one of 14 that started in 2008, is one of 47 in phase 4, and was the 29th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+
University of Colorado, Denver · Sites in United States, India
Ages 18+
Johns Hopkins University · Sites in South Africa
Ages 18+
University of Maryland, Baltimore · Sites in Botswana
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 25 · Phase 3 30 · Phase 4 47
First in 2000; this study’s year is marked. 14 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is below the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 209 across the 110 interventional studies. Of the 97 that completed or were terminated, 61 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 110 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Smoking Cessation by Pfizer: none open now, none under way, none of them phase 3. Of 43 finished, 23 (53%) have results posted.
Among the 44 studies in Smoking Cessation by Pfizer, this one is the 26th largest by enrollment of the 35 interventional ones that give a count, is one of 8 that started in 2008, is one of 11 in phase 4, and was the 24th registered.
Pfizer’s Smoking Cessation studies by the year they started, since 2000.
2 of the studies testing varenicline in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05413122Phase 3Johns Hopkins UniversityEvaluating Smoking Cessation Interventions for PWH in South Africa | 2027-08-31 |
| NCT05694637University of Maryland, BaltimoreBotswana Smoking and Abstinence Reinforcement Trial | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 110 studies testing varenicline in Smoking Cessation, from their registry updates:
Among Pfizer’s 44 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study objective is to compare neuropsychiatric adverse events in subjects treated with varenicline or placebo in a controlled setting where both groups are experiencing nicotine withdrawal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: varenicline
Drug: placebo
1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
Also known as: Chantix, Champix
1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
Change From Baseline in the Profile of Mood States (POMS): Total Mood Disturbance (TMD)
POMS TMD were responses to 65 items in 6 subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor, Fatigue, and Confusion), on 'How you feel right now?' (scale:0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely). All items were rated in the same direction except for Relaxed and Efficient in the Tension-Anxiety and Confusion subscales. TMD was the sum of the scores of all 6 subscales but weighting Vigor negatively. Summary results (TMD scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Profile of Mood States (POMS): Tension-Anxiety Subscale
POMS Tension-Anxiety subscale data were responses to 9 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction except for Relaxed. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Profile of Mood States (POMS): Depression-Dejection Subscale
POMS Depression-Dejection subscale data responses to 15 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Profile of Mood States (POMS): Anger-Hostility Subscale
POMS Anger-Hostility subscale data were responses to 12 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Profile of Mood States (POMS): Vigor Subscale
POMS Vigor subscale data were responses to 8 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Profile of Mood States (POMS): Fatigue Subscale
POMS Fatigue subscale data were responses to 7 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Profile of Mood States (POMS): Confusion Subscale
POMS Confusion subscale data were responses to 7 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction except for Efficient. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score
The MADRS measures the overall severity of depressive symptoms and is a 10-item checklist. Each item was rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Hamilton Anxiety Scale (HAM-A): Total Score
HAM-A measures treatment-related changes in generalized anxiety symptoms and is a 14-item questionnaire. Each item was scored from 0 (not present) to 4 (very severe) and a lower score indicated less affected. Total scores ranged from 0 (not affected) to 56 (very severely affected).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Aggression Total Score
The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Aggression total score was calculated by summing the weighted scores in Q1 to 4. Scores for each question ranged from 0 (no events) to 5 (very severe events). Total scores ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of agressive behaviour in a week.
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score
The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Irritability total score was calculated by summing the items in Q5 to 6. Scores for each question ranged from 0 (not at all) to 5 (extreme). Total scores ranged from 0 (no irritability) to 10 (extreme irritability).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score
The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Suicidality total score was calculated by summing the items Q7 to 7b. Scores for Q7 ranged from 0 (none) to 6 (very extreme) and scores for Q7a to 7b ranged from 0 (none) to 5 (extreme). Total scores ranged from 0 (no suicidal tendency) to 16 (extreme/very extreme suicidal tendency).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Social Dysfunction and Aggression Scale (SDAS): Total Score
The SDAS contains 11 items with 5 possible responses: 0=not present, 1=doubtful or very mild, 2=mild to moderate, 3=severe, and 4=extremely severe. The SDAS was collected 3 times a day during the inpatient abstinence period (BC). Total scores ranged from 0 (not present) to 44 (extremely severe).
Time frame: Baseline B (Week 2) to Week 4 (Period BC)
Change From Baseline in the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score
The BIS-11 is a 30-item self-report questionnaire designed to assess general impulsiveness taking into account the multifactorial nature of the construct. Possible responses to each item were: 1=rarely/never, 2=occasionally, 3=often, and 4=almost always/always. Scores of Items 1, 7, 8, 9, 10, 12, 13, 15, 20, 29 and 30 were reversed when calculating the total score. Total score ranged from 30 (less impulsive) to 120 (more impulsive).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Total Score
The MNWS total score contains 9 items (urge to smoke; depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating; restlessness; increased appetite; difficulty going to sleep; difficulty staying asleep). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Total scores were the average score for all 9 items and ranged from 0 (no withdrawal symptoms) to 4 (extreme withdrawal symptoms).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Negative Affect Domain Subscale
The MNWS negative affect domain subscale contains 4 items (depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores were the average from all 4 items and ranged from 0 (no negative affect) to 4 (extreme negative affect).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Insomnia Domain Subscale
The MNWS insomnia domain subscale contains 2 items (difficulty going to sleep; difficulty staying asleep). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores were the average of the 2 items and ranged from 0 (no insomnia) to 4 (extreme insomnia).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Urge to Smoke Subscale
The MNWS urge to smoke subscale contains 1 item (urge to smoke) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no urge to smoke) to 4 (extreme urge to smoke).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Restlessness Subscale
The MNWS restlessness subscale contains 1 item (restlessness) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no restlessness) to 4 (extreme restlessness).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Increased Appetite Subscale
The MNWS increased appetite subscale contains 1 item (increased appetite) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no increased appetite) to 4 (extreme increased appetite).
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Number of Participants Exceeding Thresholds for the Profile of Mood States (POMS): Total Score
POMS total mood disturbance (TMD) summary results were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance). Participants exceeding the threshold had an increase from baseline of 1 standard deviation of the TMD baseline T-score plus 1 or more.
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Number of Participants Exceeding Thresholds for the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score
The MADRS measures the overall severity of depressive symptoms. Total score ranged from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Participants exceeding the threshold had a MADRS total score of more than 14 out of 60. MADRS total scores exceeding 14 may represent clinically notable effective symptomatology.
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Number of Participants Exceeding Thresholds for the Hamilton Anxiety Scale (HAM-A): Total Score
HAM-A measures treatment-related changes in generalized anxiety symptoms. Total scores ranged from 0 (not affected) to 56 (very severely affected). Participants exceeding the threshold had a HAM-A total score of more than or equal to 14 out of 56. HAM-A total scores of more than or equal to 14 may reflect clinically noteworthy levels of anxiety.
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Agression Total Score
The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Aggression total score ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of agressive behaviour in a week. Participants exceeding the threshold had an OAS-m Aggression total score of more than or equal to 3 out of any number with no upper limit depending on the frequency of agressive behaviour in a week. OAS-m Aggression total scores of more than or equal to 3 reflect clinically important aggression.
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score
The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Irritability total score ranged from 0 (no irritability) to 10 (extreme irritability). Participants exceeding the threshold had an OAS-m Irritability total score of more than or equal to 2 out of 10. OAS-m Irritability total scores of more than or equal to 2 reflect clinically important irritability.
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score
The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Suicidality total score ranged from 0 (no suicidal tendency) to 16 (extreme/very extreme suicidal tendency). No threshold criterion was determined for OAS-m Suicidality total score.
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Number of Participants Exceeding Thresholds for the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score
The BIS-11 is designed to assess general impulsiveness taking into account the multifactorial nature of the construct. Total score ranged from 30 (less impulsive) to 120 (more impulsive). Participants exceeding the threshold had a BIS-11 total score more than or equal to 70 out of 120. BIS-11 total scores of more than or equal to 70 could reflect clinically important and potentially pathological impulsivity.
Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Number of Participants Exceeding Thresholds for the Social Dysfunction and Aggression Scale (SDAS): Total Score
SDAS total scores ranged from 0 (not present) to 44 (extremely severe). Participants exceeding the threshold had a SDAS total score of more than 6 out of 44.
Time frame: Baseline B (Week 2) to Week 4 (Period BC)
Number of Participants With Carbon Monoxide Confirmed Daily Smoking Cessation
Participants who reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory, which was used to collect the information of cigarette or other nicotine use during the study) and who did not have carbon monoxide of more than 10 parts per million at any time from Week 9 to Week 12
Time frame: Week 9 to Week 12
Number of Participants With 7-day Point Prevalence of Abstinence (Smoking Cessation)
Participants who reported no smoking and no use of other nicotine-containing products since the last study visit (during treatment) in the previous 7 days and who did not have carbon monoxide of more than 10 parts per million for that observation (if measured).
Time frame: Week 5 to Week 13
Change From Baseline in the Number of Cigarettes Smoked Per Day
Time frame: Baseline (Week 0) to Week 2
| Milestone | Varenicline | Placebo |
|---|---|---|
| Started | 55 | 55 |
| Completed | 50 | 54 |
| Not completed | 5 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
POMS TMD were responses to 65 items in 6 subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor, Fatigue, and Confusion), on 'How you feel right now?' (scale:0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely). All items were rated in the same direction except for Relaxed and Efficient in the Tension-Anxiety and Confusion subscales. TMD was the sum of the scores of all 6 subscales but weighting Vigor negatively. Summary results (TMD scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=55, 55) | 0.06 ± 0.39 | -0.66 ± 0.36 |
| Period AC (n=55, 55) | 0.30 ± 0.35 | -0.17 ± 0.36 |
| Period AD (n=55, 55) | 0.95 ± 0.43 | 0.03 ± 0.41 |
| Period AE (n=55, 55) | 0.72 ± 0.36 | 0.22 ± 0.37 |
| Period BC (n=53, 54) | 0.48 ± 0.35 | 0.91 ± 0.31 |
| Period BD (n=53, 54) | 1.07 ± 0.47 | 1.04 ± 0.39 |
| Period BE (n=54, 54) | 0.59 ± 0.37 | 0.96 ± 0.36 |
POMS Tension-Anxiety subscale data were responses to 9 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction except for Relaxed. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=55, 55) | 0.30 ± 0.30 | -0.31 ± 0.25 |
| Period AC (n=55, 55) | 0.15 ± 0.25 | -0.26 ± 0.21 |
| Period AD (n=55, 55) | 0.31 ± 0.24 | -0.18 ± 0.27 |
| Period AE (n=55, 55) | 0.01 ± 0.24 | -0.43 ± 0.20 |
| Period BC (n=53, 54) | -0.01 ± 0.24 | -0.10 ± 0.25 |
| Period BD (n=53, 54) | 0.06 ± 0.23 | -0.16 ± 0.29 |
| Period BE (n=54, 54) | -0.35 ± 0.19 | -0.58 ± 0.21 |
POMS Depression-Dejection subscale data responses to 15 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=55, 55) | 0.38 ± 0.25 | -0.24 ± 0.18 |
| Period AC (n=55, 55) | 0.50 ± 0.24 | -0.24 ± 0.13 |
| Period AD (n=55, 55) | 0.56 ± 0.27 | -0.10 ± 0.16 |
| Period AE (n=55, 55) | 0.44 ± 0.24 | 0.00 ± 0.19 |
| Period BC (n=53, 54) | 0.51 ± 0.27 | 0.03 ± 0.13 |
| Period BD (n=53, 54) | 0.49 ± 0.32 | 0.10 ± 0.14 |
| Period BE (n=54, 54) | 0.32 ± 0.23 | 0.23 ± 0.20 |
POMS Anger-Hostility subscale data were responses to 12 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=55, 55) | 0.16 ± 0.36 | -0.69 ± 0.25 |
| Period AC (n=55, 55) | -0.04 ± 0.31 | -0.89 ± 0.16 |
| Period AD (n=55, 55) | 0.24 ± 0.36 | -1.00 ± 0.22 |
| Period AE (n=55, 55) | 0.15 ± 0.30 | -0.68 ± 0.15 |
| Period BC (n=53, 54) | -0.00 ± 0.29 | -0.52 ± 0.15 |
| Period BD (n=53, 54) | 0.22 ± 0.41 | -0.65 ± 0.19 |
| Period BE (n=54, 54) | -0.05 ± 0.25 | -0.43 ± 0.18 |
POMS Vigor subscale data were responses to 8 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=55, 55) | 0.16 ± 0.86 | 0.98 ± 0.75 |
| Period AC (n=55, 55) | -1.34 ± 0.87 | -1.15 ± 0.75 |
| Period AD (n=55, 55) | -3.30 ± 1.18 | -1.14 ± 0.97 |
| Period AE (n=55, 55) | -2.80 ± 1.00 | -1.82 ± 0.91 |
| Period BC (n=53, 54) | -1.49 ± 0.81 | -3.44 ± 0.83 |
| Period BD (n=53, 54) | -3.22 ± 1.25 | -3.22 ± 1.11 |
| Period BE (n=54, 54) | -2.28 ± 1.02 | -3.37 ± 1.04 |
POMS Fatigue subscale data were responses to 7 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=55, 55) | -0.14 ± 0.29 | -0.65 ± 0.29 |
| Period AC (n=55, 55) | -0.29 ± 0.28 | -0.83 ± 0.24 |
| Period AD (n=55, 55) | -0.58 ± 0.26 | -0.76 ± 0.27 |
| Period AE (n=55, 55) | -0.32 ± 0.27 | -0.59 ± 0.24 |
| Period BC (n=53, 54) | 0.37 ± 0.32 | -0.22 ± 0.23 |
| Period BD (n=53, 54) | -0.20 ± 0.29 | -0.13 ± 0.30 |
| Period BE (n=54, 54) | -0.16 ± 0.29 | -0.26 ± 0.25 |
POMS Confusion subscale data were responses to 7 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction except for Efficient. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=55, 55) | 0.14 ± 0.19 | -0.09 ± 0.12 |
| Period AC (n=55, 55) | 0.03 ± 0.17 | -0.18 ± 0.10 |
| Period AD (n=55, 55) | 0.10 ± 0.18 | -0.11 ± 0.13 |
| Period AE (n=55, 55) | -0.01 ± 0.15 | -0.03 ± 0.13 |
| Period BC (n=53, 54) | 0.02 ± 0.22 | -0.07 ± 0.11 |
| Period BD (n=53, 54) | 0.07 ± 0.22 | -0.02 ± 0.15 |
| Period BE (n=54, 54) | -0.14 ± 0.18 | -0.02 ± 0.16 |
The MADRS measures the overall severity of depressive symptoms and is a 10-item checklist. Each item was rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 1.05 ± 0.37 | 0.83 ± 0.25 |
| Period AC (n=54, 54) | 2.28 ± 0.35 | 1.84 ± 0.30 |
| Period AD (n=54, 54) | 1.19 ± 0.29 | 1.41 ± 0.37 |
| Period AE (n=55, 54) | 1.52 ± 0.21 | 1.50 ± 0.28 |
| Period BC (n=53, 54) | 2.27 ± 0.50 | 1.69 ± 0.48 |
| Period BD (n=53, 54) | -0.10 ± 0.35 | 0.33 ± 0.53 |
| Period BE (n=53, 54) | 0.40 ± 0.24 | 0.49 ± 0.30 |
HAM-A measures treatment-related changes in generalized anxiety symptoms and is a 14-item questionnaire. Each item was scored from 0 (not present) to 4 (very severe) and a lower score indicated less affected. Total scores ranged from 0 (not affected) to 56 (very severely affected).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 1.01 ± 0.32 | 0.75 ± 0.27 |
| Period AC (n=54, 54) | 2.69 ± 0.37 | 2.16 ± 0.28 |
| Period AD (n=54, 54) | 1.95 ± 0.41 | 1.86 ± 0.42 |
| Period AE (n=55, 54) | 1.75 ± 0.28 | 1.61 ± 0.26 |
| Period BC (n=53, 54) | 3.15 ± 0.56 | 2.65 ± 0.47 |
| Period BD (n=53, 54) | 0.74 ± 0.47 | 0.77 ± 0.62 |
| Period BE (n=53, 54) | 0.73 ± 0.30 | 0.81 ± 0.29 |
The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Aggression total score was calculated by summing the weighted scores in Q1 to 4. Scores for each question ranged from 0 (no events) to 5 (very severe events). Total scores ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of agressive behaviour in a week.
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 0.13 ± 0.27 | 0.48 ± 0.66 |
| Period AC (n=54, 54) | 0.82 ± 0.37 | 0.72 ± 0.39 |
| Period AD (n=54, 54) | 2.24 ± 1.75 | 0.75 ± 0.34 |
| Period AE (n=55, 54) | 1.27 ± 0.70 | 0.77 ± 0.48 |
| Period BC (n=53, 54) | 0.83 ± 0.63 | 0.22 ± 0.38 |
| Period BD (n=53, 54) | 1.94 ± 2.27 | -0.15 ± 0.44 |
| Period BE (n=53, 54) | 1.00 ± 0.88 | -0.13 ± 0.23 |
The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Irritability total score was calculated by summing the items in Q5 to 6. Scores for each question ranged from 0 (not at all) to 5 (extreme). Total scores ranged from 0 (no irritability) to 10 (extreme irritability).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 0.01 ± 0.10 | 0.01 ± 0.09 |
| Period AC (n=54, 54) | 0.43 ± 0.10 | 0.41 ± 0.09 |
| Period AD (n=54, 54) | 0.46 ± 0.17 | 0.35 ± 0.17 |
| Period AE (n=55, 54) | 0.32 ± 0.10 | 0.24 ± 0.08 |
| Period BC (n=53, 54) | 0.82 ± 0.16 | 0.78 ± 0.16 |
| Period BD (n=53, 54) | 0.53 ± 0.19 | 0.35 ± 0.24 |
| Period BE (n=53, 54) | 0.38 ± 0.11 | 0.25 ± 0.08 |
The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Suicidality total score was calculated by summing the items Q7 to 7b. Scores for Q7 ranged from 0 (none) to 6 (very extreme) and scores for Q7a to 7b ranged from 0 (none) to 5 (extreme). Total scores ranged from 0 (no suicidal tendency) to 16 (extreme/very extreme suicidal tendency).
No measurements were reported for this outcome.
The SDAS contains 11 items with 5 possible responses: 0=not present, 1=doubtful or very mild, 2=mild to moderate, 3=severe, and 4=extremely severe. The SDAS was collected 3 times a day during the inpatient abstinence period (BC). Total scores ranged from 0 (not present) to 44 (extremely severe).
No measurements were reported for this outcome.
The BIS-11 is a 30-item self-report questionnaire designed to assess general impulsiveness taking into account the multifactorial nature of the construct. Possible responses to each item were: 1=rarely/never, 2=occasionally, 3=often, and 4=almost always/always. Scores of Items 1, 7, 8, 9, 10, 12, 13, 15, 20, 29 and 30 were reversed when calculating the total score. Total score ranged from 30 (less impulsive) to 120 (more impulsive).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 0.34 ± 0.56 | -0.07 ± 0.50 |
| Period AC (n=54, 54) | 0.45 ± 0.62 | 0.37 ± 0.53 |
| Period AD (n=54, 54) | 1.34 ± 0.74 | 1.28 ± 1.03 |
| Period AE (n=55, 54) | 1.19 ± 0.69 | 0.90 ± 0.64 |
| Period BC (n=53, 54) | 0.04 ± 0.49 | 0.97 ± 0.43 |
| Period BD (n=53, 54) | 1.07 ± 0.49 | 1.81 ± 0.92 |
| Period BE (n=53, 54) | 0.85 ± 0.52 | 1.28 ± 0.44 |
The MNWS total score contains 9 items (urge to smoke; depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating; restlessness; increased appetite; difficulty going to sleep; difficulty staying asleep). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Total scores were the average score for all 9 items and ranged from 0 (no withdrawal symptoms) to 4 (extreme withdrawal symptoms).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 0.13 ± 0.04 | 0.05 ± 0.04 |
| Period AC (n=54, 54) | 0.10 ± 0.03 | 0.11 ± 0.03 |
| Period AD (n=54, 54) | 0.07 ± 0.03 | 0.05 ± 0.03 |
| Period AE (n=55, 54) | -0.01 ± 0.02 | 0.04 ± 0.03 |
| Period BC (n=53, 54) | -0.04 ± 0.04 | 0.10 ± 0.06 |
| Period BD (n=53, 54) | -0.08 ± 0.03 | 0.02 ± 0.04 |
| Period BE (n=53, 54) | -0.15 ± 0.01 | -0.05 ± 0.03 |
The MNWS negative affect domain subscale contains 4 items (depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores were the average from all 4 items and ranged from 0 (no negative affect) to 4 (extreme negative affect).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 0.06 ± 0.03 | 0.01 ± 0.02 |
| Period AC (n=54, 54) | 0.10 ± 0.03 | 0.09 ± 0.03 |
| Period AD (n=54, 54) | 0.07 ± 0.03 | 0.03 ± 0.03 |
| Period AE (n=55, 54) | 0.05 ± 0.02 | 0.07 ± 0.03 |
| Period BC (n=53, 54) | 0.07 ± 0.05 | 0.15 ± 0.05 |
| Period BD (n=53, 54) | -0.01 ± 0.03 | 0.02 ± 0.05 |
| Period BE (n=53, 54) | -0.02 ± 0.02 | 0.03 ± 0.03 |
The MNWS insomnia domain subscale contains 2 items (difficulty going to sleep; difficulty staying asleep). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores were the average of the 2 items and ranged from 0 (no insomnia) to 4 (extreme insomnia).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 0.07 ± 0.04 | 0.12 ± 0.06 |
| Period AC (n=54, 54) | 0.15 ± 0.04 | 0.17 ± 0.05 |
| Period AD (n=54, 54) | 0.04 ± 0.03 | 0.10 ± 0.04 |
| Period AE (n=55, 54) | 0.06 ± 0.02 | 0.13 ± 0.06 |
| Period BC (n=53, 54) | 0.14 ± 0.07 | 0.09 ± 0.08 |
| Period BD (n=53, 54) | -0.04 ± 0.05 | 0.01 ± 0.06 |
| Period BE (n=53, 54) | -0.06 ± 0.02 | -0.01 ± 0.06 |
The MNWS urge to smoke subscale contains 1 item (urge to smoke) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no urge to smoke) to 4 (extreme urge to smoke).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | -0.60 ± 0.10 | -0.29 ± 0.09 |
| Period AC (n=54, 54) | -1.40 ± 0.09 | -0.97 ± 0.09 |
| Period AD (n=54, 54) | -2.17 ± 0.12 | -2.03 ± 0.12 |
| Period AE (n=55, 54) | -1.90 ± 0.09 | -1.55 ± 0.09 |
| Period BC (n=53, 54) | -1.59 ± 0.12 | -1.14 ± 0.14 |
| Period BD (n=53, 54) | -1.66 ± 0.14 | -1.58 ± 0.15 |
| Period BE (n=53, 54) | -1.56 ± 0.10 | -1.29 ± 0.11 |
The MNWS restlessness subscale contains 1 item (restlessness) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no restlessness) to 4 (extreme restlessness).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 0.06 ± 0.04 | 0.08 ± 0.04 |
| Period AC (n=54, 54) | 0.10 ± 0.04 | 0.11 ± 0.04 |
| Period AD (n=54, 54) | 0.09 ± 0.04 | 0.04 ± 0.03 |
| Period AE (n=55, 54) | 0.03 ± 0.02 | 0.05 ± 0.03 |
| Period BC (n=53, 54) | 0.07 ± 0.05 | 0.08 ± 0.05 |
| Period BD (n=53, 54) | 0.03 ± 0.02 | -0.03 ± 0.01 |
| Period BE (n=53, 54) | -0.04 ± 0.02 | -0.03 ± 0.03 |
The MNWS increased appetite subscale contains 1 item (increased appetite) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no increased appetite) to 4 (extreme increased appetite).
| scores on a scale | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 0.14 ± 0.07 | 0.02 ± 0.05 |
| Period AC (n=54, 54) | 0.10 ± 0.05 | 0.12 ± 0.06 |
| Period AD (n=54, 54) | 0.11 ± 0.09 | 0.15 ± 0.09 |
| Period AE (n=55, 54) | -0.00 ± 0.05 | 0.04 ± 0.06 |
| Period BC (n=53, 54) | -0.03 ± 0.07 | 0.16 ± 0.08 |
| Period BD (n=53, 54) | -0.01 ± 0.09 | 0.15 ± 0.10 |
| Period BE (n=53, 54) | -0.10 ± 0.04 | -0.03 ± 0.06 |
POMS total mood disturbance (TMD) summary results were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance). Participants exceeding the threshold had an increase from baseline of 1 standard deviation of the TMD baseline T-score plus 1 or more.
| participants | Varenicline | Placebo |
|---|---|---|
| Period AB (n=55, 55) | 14 | 11 |
| Period AC (n=55, 55) | 32 | 35 |
| Period AD (n=55, 55) | 37 | 38 |
| Period AE (n=55, 55) | 38 | 38 |
| Period BC (n=53, 54) | 27 | 33 |
| Period BD (n=53, 54) | 30 | 36 |
| Period BE (n=54, 54) | 32 | 38 |
The MADRS measures the overall severity of depressive symptoms. Total score ranged from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Participants exceeding the threshold had a MADRS total score of more than 14 out of 60. MADRS total scores exceeding 14 may represent clinically notable effective symptomatology.
| participants | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 2 | 0 |
| Period AC (n=54, 54) | 7 | 3 |
| Period AD (n=54, 54) | 8 | 3 |
| Period AE (n=55, 54) | 11 | 8 |
| Period BC (n=53, 54) | 5 | 3 |
| Period BD (n=53, 54) | 6 | 3 |
| Period BE (n=54, 54) | 9 | 8 |
HAM-A measures treatment-related changes in generalized anxiety symptoms. Total scores ranged from 0 (not affected) to 56 (very severely affected). Participants exceeding the threshold had a HAM-A total score of more than or equal to 14 out of 56. HAM-A total scores of more than or equal to 14 may reflect clinically noteworthy levels of anxiety.
| participants | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 0 | 2 |
| Period AC (n=54, 54) | 9 | 7 |
| Period AD (n=54, 54) | 12 | 7 |
| Period AE (n=55, 54) | 16 | 10 |
| Period BC (n=53, 54) | 9 | 6 |
| Period BD (n=53, 54) | 12 | 6 |
| Period BE (n=54, 54) | 16 | 9 |
The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Aggression total score ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of agressive behaviour in a week. Participants exceeding the threshold had an OAS-m Aggression total score of more than or equal to 3 out of any number with no upper limit depending on the frequency of agressive behaviour in a week. OAS-m Aggression total scores of more than or equal to 3 reflect clinically important aggression.
| participants | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 9 | 6 |
| Period AC (n=54, 54) | 20 | 21 |
| Period AD (n=54, 54) | 21 | 23 |
| Period AE (n=55, 54) | 28 | 31 |
| Period BC (n=53, 54) | 15 | 19 |
| Period BD (n=53, 54) | 18 | 21 |
| Period BE (n=54, 54) | 27 | 30 |
The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Irritability total score ranged from 0 (no irritability) to 10 (extreme irritability). Participants exceeding the threshold had an OAS-m Irritability total score of more than or equal to 2 out of 10. OAS-m Irritability total scores of more than or equal to 2 reflect clinically important irritability.
| participants | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 10 | 11 |
| Period AC (n=54, 54) | 32 | 34 |
| Period AD (n=54, 54) | 36 | 36 |
| Period AE (n=55, 54) | 41 | 39 |
| Period BC (n=53, 54) | 31 | 31 |
| Period BD (n=53, 54) | 35 | 33 |
| Period BE (n=54, 54) | 40 | 38 |
The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Suicidality total score ranged from 0 (no suicidal tendency) to 16 (extreme/very extreme suicidal tendency). No threshold criterion was determined for OAS-m Suicidality total score.
No measurements were reported for this outcome.
The BIS-11 is designed to assess general impulsiveness taking into account the multifactorial nature of the construct. Total score ranged from 30 (less impulsive) to 120 (more impulsive). Participants exceeding the threshold had a BIS-11 total score more than or equal to 70 out of 120. BIS-11 total scores of more than or equal to 70 could reflect clinically important and potentially pathological impulsivity.
| participants | Varenicline | Placebo |
|---|---|---|
| Period AB (n=54, 54) | 1 | 0 |
| Period AC (n=54, 54) | 1 | 2 |
| Period AD (n=54, 54) | 1 | 2 |
| Period AE (n=55, 54) | 5 | 5 |
| Period BC (n=53, 54) | 1 | 2 |
| Period BD (n=53, 54) | 1 | 2 |
| Period BE (n=54, 54) | 5 | 5 |
SDAS total scores ranged from 0 (not present) to 44 (extremely severe). Participants exceeding the threshold had a SDAS total score of more than 6 out of 44.
| participants | Varenicline | Placebo |
|---|---|---|
| Number of Participants Exceeding Thresholds for the Social Dysfunction and Aggression Scale (SDAS): Total Score | 2 | 1 |
Participants who reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory, which was used to collect the information of cigarette or other nicotine use during the study) and who did not have carbon monoxide of more than 10 parts per million at any time from Week 9 to Week 12
| participants | Varenicline | Placebo |
|---|---|---|
| Number of Participants With Carbon Monoxide Confirmed Daily Smoking Cessation | 16 | 10 |
Participants who reported no smoking and no use of other nicotine-containing products since the last study visit (during treatment) in the previous 7 days and who did not have carbon monoxide of more than 10 parts per million for that observation (if measured).
| participants | Varenicline | Placebo |
|---|---|---|
| Week 5 (n=55, 55) | 19 | 16 |
| Week 6 (n=55, 55) | 23 | 12 |
| Week 7 (n=55, 55) | 20 | 17 |
| Week 8 (n=55, 55) | 21 | 15 |
| Week 9 (n=55, 55) | 25 | 14 |
| Week 10 (n=55, 55) | 17 | 17 |
| Week 11 (n=55, 55) | 20 | 18 |
| Week 12 (n=55, 55) | 19 | 15 |
| Week 13 (n=55, 55) | 23 | 15 |
| cigarettes smoked per day | Varenicline | Placebo |
|---|---|---|
| Day 2 (n=55, 54) | -0.1 ± 3.6 | -0.2 ± 3.7 |
| Day 3 (n=55, 54) | -0.6 ± 4.1 | 0.0 ± 3.9 |
| Day 4 (n=55, 54) | -1.8 ± 5.0 | -0.3 ± 3.7 |
| Day 5 (n=55, 54) | -1.0 ± 5.2 | -0.4 ± 4.0 |
| Day 6 (n=54, 54) | -1.3 ± 5.9 | 0.1 ± 4.5 |
| Day 7 (n=54, 54) | -1.8 ± 4.9 | -0.3 ± 5.0 |
| Day 8 (n=54, 54) | -1.7 ± 5.0 | 0.4 ± 4.3 |
| Day 9 (n=52, 54) | -1.0 ± 5.1 | 0.1 ± 4.2 |
| Day 10 (n=52, 54) | -1.7 ± 5.7 | -0.4 ± 6.1 |
| Day 11 (n=53, 54) | -1.8 ± 5.3 | -0.4 ± 6.3 |
| Day 12 (n=53, 54) | -0.7 ± 6.6 | -0.2 ± 6.3 |
| Day 13 (n=53, 54) | -1.4 ± 5.6 | -0.1 ± 6.1 |
| Day 14 (n=36, 38) | -17.2 ± 8.6 | -15.7 ± 6.6 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline | — | 0/55 (0%) | 54/55 (98.2%) |
| Placebo | — | 0/55 (0%) | 52/55 (94.5%) |
| Event | Varenicline | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 18/55 | 16/55 |
| HeadacheNervous system disorders | 18/55 | 15/55 |
| IrritabilityGeneral disorders | 17/55 | 17/55 |
| Upper respiratory tract infectionInfections and infestations | 12/55 | 17/55 |
| InsomniaPsychiatric disorders | 17/55 | 10/55 |
| SomnolenceNervous system disorders | 11/55 | 8/55 |
| Abdominal painGastrointestinal disorders | 10/55 | 5/55 |
| Chapped lipsGastrointestinal disorders | 10/55 | 7/55 |
| Increased appetiteMetabolism and nutrition disorders | 4/55 | 9/55 |
| ConstipationGastrointestinal disorders | 8/55 | 3/55 |
| Age, Customized(Participants) | Varenicline | Placebo | Total |
|---|---|---|---|
| Between 18 and 44 years | 47 | 47 | 94 |
| Between 45 and 64 years | 7 | 8 | 15 |
| >= 65 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Varenicline | Placebo | Total |
|---|---|---|---|
| Female | 22 | 15 | 37 |
| Male | 33 | 40 | 73 |
The record gives a start of Sep 2008, a primary completion of Jul 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline